NLRP3 and metabolic dysfunction-associated steatotic liver disease: In animal models, ezetimibe reduced inflammatory response [50,51,52] and promoted autophagy, which resulted in neuroprotection or improvement of nonalcoholic fatty liver disease (NAFLD) [24,53] via AMP protein kinase (AMPK) activation and inhibition of NLR family pyrin domain containing 3 (NLRP3) inflammasome [23].